Twenty-Year Survival in Glioblastoma: A Case Report and Molecular Profile
- Research Associate, Minneapolis Radiation Oncology, Minneapolis, MN (United States)
- Massachusetts General Hospital/Harvard Medical School, Boston, MA (United States)
- UT-MD Anderson Cancer Center, Department of Pathology, Houston, TX (United States)
- Johns Hopkins School of Medicine, Division of Neuropathology, Baltimore, MD (United States)
- Ridgeview Medical Center, Department of Medical Oncology, Waconia, MN (United States)
- University of Minnesota Gamma Knife Center, Minneapolis, MN (United States)
Background: The prognosis for patients with glioblastoma (GB) remains grim. Historically, the median survival has been 6 to 9 months. Recent research has improved the outcome slightly. A computer search of the literature reveals few long-term survivors. Method: Presented here is a case report of a 20-year survivor of GB, with pathologic review to confirm the diagnosis. A battery of molecular studies was performed to develop a molecular profile of this unique patient. Results: The results of the molecular genetic testing for this most unusual patient were as follows: (1) methylguanine methyl transferase (MGMT) was methylated, (2) p53 positive, (3) PTEN tumor suppressor gene positive, (4) protein kinase AKT (pAKT) negative, and (5) epidermal growth factor receptor negative. Conclusion: To our knowledge, this is the longest survival of any patient in the literature whose initial diagnosis was GB. Triple-positive GBM patients (MGMT methylated, PTEN, and p53 positive) are uncommon but may be associated with a better prognosis. Further research is needed to confirm whether this molecular profile is prognostic of prolonged survival. Molecular genetics will determine future treatment and prognosis in GB.
- OSTI ID:
- 21367516
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 75, Issue 4; Other Information: DOI: 10.1016/j.ijrobp.2008.12.054; PII: S0360-3016(09)00008-X; Copyright (c) 2009 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
MGMT Gene Promoter Methylation as a Potent Prognostic Factor in Glioblastoma Treated With Temozolomide-Based Chemoradiotherapy: A Single-Institution Study
Using the apparent diffusion coefficient to identifying MGMT promoter methylation status early in glioblastoma: importance of analytical method